Research programme: antibacterial therapeutics - Gunsynd

Drug Profile

Research programme: antibacterial therapeutics - Gunsynd

Alternative Names: SYN 0017; SYN 0096; SYN 0854; SYN 101; SYN 102; SYN 1093; SYN 1163

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Syntopix
  • Developer Gunsynd
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Acne; Staphylococcal infections

Highest Development Phases

  • No development reported Acne; Mouth disorders; Staphylococcal infections

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Acne in United Kingdom (Topical)
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Mouth-disorders in United Kingdom (Topical)
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Staphylococcal-infections in United Kingdom (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top